For many types of cancer, early detection can lead to better outcomes for patients. While scientists are developing new blood tests that analyze DNA to aid in earlier detection, these new technologies have limitations, including cost and sensitivity.
To make the EU the place where AI excellence thrives from the lab to the market, the European Union is setting up world-class Testing and Experimentation Facilities (TEFs) for AI.
Together with Member States, the Commission is co-funding the TEFs to support AI developers to bring trustworthy AI to the market more efficiently, and facilitate its uptake in Europe.
Current DNA mutation software detectors, while scanning the 3 billion bases of the human genome, are not well suited to discern mosaic mutations hiding among normal DNA sequences.